Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

Table 1 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy

Variable	Total, n = 11938	SVR, n = 11629	Non-SVR, n = 309	P value
Sex, n (%)
Male	5762 (48.3)	5553 (47.8)	209 (67.6)	< 0.001
Female	6176 (51.7)	6076 (52.2)	100 (32.4)
Age	52.24 (51.77-52.70)	52.24 (51.77-52.71)	52.16 (50.74-53.58)	0.869
BMI (kg/m2)	26.47 (26.29-26.64)	26.45 (26.26-26.62)	27.20 (26.68-27.72)	< 0.001
Fibrosis
F0	277 (1.9)	225 (99.1)	2 (0.9)
F1	4539 (38.8)	4469 (98.5)	70 (1.5)
F2	2249 (19.2)	2204 (98.0)	45 (2.0)	< 0.001
F3	1717 (14.7)	1684 (98.1)	33 (1.9)
F4	2974 (25.4)	2828 (95.1)	146 (4.9)
Liver stiffness (kPa)	12.72 (12.45-12.99)	12.53 (12.29-12.76)	20.27 (14.78-25.76)	< 0.001
Child Pugh, n (%)
A	11320 (96.9)	11050 (97.1)	270 (89.7)
B	346 (3.0)	315 (2.8)	31 (10.3)	< 0.001
C	13 (0.1)	13 (0.1)	0 (0.0)
MELD score	7.81 (7.76-7.85)	7.79 (7.74-7.84)	8.39 (8.11-8.67)	< 0.001
Esophageal varices, n (%)
Yes	989 (10.5)	922 (10.1)	67 (27.1)	< 0.001
No	8413 (89.5)	8233 (89.9)	180 (72.9)
Ascites at the start of the treatment, n (%)
No	11742 (98.8)	11444 (98.9)	298 (96.4)
Moderate	136 (1.2)	125 (1.1)	11 (3.6)	< 0.001
Tense	6 (0.0)	6 (0.0)	0 (0.0)
Encephalopathy at the start of the treatment, n (%)
No	11808 (99.4)	11507 (99.5)	301 (97.8)
Grade 1-2	67 (0.6)	60 (0.5)	7 (2.2)	0.001
Grade 3-4	1 (0.0)	1 (0.0)	0 (0.0)
History of hepatocellular carcinoma, n (%)
Yes	179 (1.5)	167 (1.5)	12 (4.1)	< 0.001
No	11515 (98.5)	11231 (98.5)	284 (95.9)
Extrahepatic manifestations, n (%)
Yes	948 (8.3)	916 (8.2)	32 (10.8)	0.282
No	10513 (91.7)	10248 (91.8)	265 (89.2)
HIV coinfection, n (%)
Yes	587 (5.0)	564 (4.9)	23 (7.6)	0.098
No	11161 (95.0)	10881 (95.1)	280 (92.4)
HBV coinfection, n (%)
Yes	1570 (13.5)	1526 (13.4)	44 (14.6)	0.851
No	10098 (86.5)	9840 (86.6)	258 (85.4)
HBsAg(+), n (%))	124 (8.0)	122 (8.1)	2 (4.5)	0.543
Reactivation of HBV infection, n (%)
Yes	11 (0.1)	11 (0.1)	0 (0.0)	0.510
No	10707 (99.9)	10435 (99.9)	272 (100.0)
History of liver transplantation, n (%)
Yes	146 (1.2)	144 (1.3)	2 (0.7)	0.576
No	11555 (98.8)	11253 (98.7)	302 (99.3)
Course of treatment, n (%)
As planned	11516 (97.1)	11238 (97.3)	278 (90.2)
Terminated early	86 (0.7)	71 (0.6)	15 (4.9)	< 0.001
Modified	257 (2.2)	242 (2.1)	15 (4.9)
Ascites appearing while on treatment, n (%)
Yes	64 (0.5)	57 (0.5)	7 (2.3)	< 0.001
No	11773 (99.5)	11473 (99.5)	300 (97.7)
Encephalopathy appearing while on treatment, n (%)
Yes	43 (0.4)	35 (0.3)	8 (2.6)	< 0.001
No	11773 (99.6)	11474 (99.7)	299 (97.4)
Gastrointestinal bleeding while on treatment, n (%)
Yes	16 (0.1)	14 (0.1)	2 (0.7)	0.044
No	11798 (99.9)	11494 (99.9)	304 (99.3)

SVR: Sustained virologic response; BMI: Body mass index; MELD: Model for End-stage Liver Disease; HBV: Hepatitis B virus; INR: International normalized ratio; PLT: Platelets; ALT: Alanine aminotransferase; eGFR: Estimated glomerular filtration rate; HCV: Hepatitis C virus.